The Global Pterygium Drug Market is expected to grow with a CAGR of 6.2% in the forecast period of 2022 to 2029. The years considered for the study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-pterygium-drug-market

The global pterygium drug market is highly fragmented and has several key players. The market has witnessed increased strategic developments owing to a favorable market scenario.  

The major players in the global pterygium drug market are introducing a strong range of product portfolios and adopting strategic initiatives such as acquisition, agreement, business expansion, awards, and recognition in the market. This helped companies to maximize sales with an enhanced product portfolio.  

For Instance:

• In April 2021, Alcon announced the launch of Systane hydration multi-dose preservative-free lubricating eye drops in the U.S. The product is a new option for patients suffering from aqueous deficient dry eye and acts as a protectant for further relief from irritation and dryness of the eye. This helped the company to increase its portfolio.

Alcon is the dominating player in the Global pterygium drug market. The other key players existing in the market are Johnson & Johnson Services, Inc., Novartis AG, Akorn Operating Company L.L.C., Bausch & Lomb Incorporated, AbbVie Inc., Prestige Consumer Healthcare Inc.,  Spectra Vision Care,  Théa Laboratories,  Wellona Pharma,  SAGER PHARMA,  Maya Biotech Private Limited,  EYERIS VISIONCARE Pvt. Ltd., Sylentis, Bayer AG, Zydus Group, Amneal Pharmaceuticals L.L.C.,  OASIS Medical, Similasan Corporation, Alcon, and Santen Pharmaceutical Co., Ltd. among others.

Alcon

Alcon is headquartered in Geneva, Switzerland, and was founded in 1945. The company is engaged in offering products in the segments, including vision care and surgical care. The various product categories of the company include Ocular Health, Contact Lenses & Solutions, Cataract Surgery, Vitreoretinal Surgery, and Glaucoma, in which ocular health is the market-focused category.  

For Instance:

• In May 2022, Alcon announced the acquisition of EYSUVIS (loteprednol etabonate suspension) pharmaceutical eye drop from Kala Pharmaceuticals, Inc. The acquisition will complement the company's Systane family of eye drops which includes preservative-free formulations, among others.
• In January 2022, Alcon announced the launch of Systane complete preservative-free lubricant eye drops in Europe. The product works to provide all-in-one dry eye relief with one drop by hydrating the layers of the tear film. This has helped the company to increase its product portfolio

The company has a wide presence across North America, Europe, Asia-Pacific, South America, Middle East, and Africa. In addition, the company also generates its revenue from various subsidiaries, including WaveLight GmbH (Germany), Ivantis, Inc. (U.S.), CIBA Vision Johor Sdn. Bhd (Malaysia), LenSx Lasers Inc. (U.S.), Alcon Pharmaceutical del Perú, S.A. (Peru), among others.

AbbVie Inc.

AbbVie Inc. is headquartered in Illinois, U.S.A, founded in 2013. The company is focusing on addressing some of the world's greatest health challenges by discovering, developing, and commercializing advanced therapies that impact people's lives. The various product categories of the company include immunology products, oncology products, aesthetics products, neuroscience products, eye care products, women's health products, and other key products in which eye care products are market-focused.

For Instance,

• In February 2021, AbbVie Inc. launched REFRESH® DIGITAL, a new lubricant eye drop formulated to specifically relieve dryness and irritation that may occur from prolonged screen time. A scientific advancement, REFRESH® DIGITAL features proprietary HydroCell™ technology that supports all three tear film layers to keep eyes hydrated. The product launch helped the company to expand its eye care product portfolio and to earn a lucrative revenue growth across several markets

The company has a presence across North America, Europe, Europe, Asia-Pacific, Middle East, Africa, U.K., and South America. In addition, the company also generates its revenue from various subsidiaries, including AbbVie Aviation L.L.C. Illinois, AbbVie Biopharmaceuticals L.L.C. Delaware, AbbVie Bioresearch Center Inc.  Delaware, AbbVie Biotech Ventures Inc.  Delaware, AbbVie S.A.  Argentina, Allergan Productos Farmaceuticos S.A.  Argentina, Allergan Australia Pty Limited Australia, Elastagen Pty Ltd  Australia among others.

Bausch & Lomb Incorporated

Bausch & Lomb Incorporated is headquartered in Quebec, Canada, and was founded in 1853. The company is engaged in improving people's lives with health care products. The various product categories of the company include contact lenses, lens care, over-the-counter eye care + supplements, R.X. pharmaceuticals, diagnostics, surgical, optical accessories, and safety and industrial glasses + eyewear cleaning, which over-the-counter eye care + supplements is the market focused category.  

For Instance,

• In July 2021, Bausch & Lomb Incorporated, a leading global eye health business of Bausch Health Companies Inc., launched Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes in the U.S. Both products are preservative-free and uniquely formulated with naturally inspired ingredients to relieve symptoms associated with irritated, dry eyes. This expanded the product portfolio and generated revenue that increased the revenue of the company

The company has a presence across North America, Europe, Asia-Pacific, South America, Middle East, and Africa. In addition, the company also generates its revenue from various subsidiaries Bausch & Lomb Argentina S.R.L. (Argentina), Waicon Vision S.A. (Argentina), Bausch & Lomb (Australia) Pty Limited (Australia), Bausch Health Australia Pty Limited (Australia), Wirra Holdings Pty Limited (Australia), Bausch Health Closed Joint-Stock Company (Belarus), Bausch & Lomb Pharma S.A. (Belgium) and among others.